Soluble CD93 in Serum as a Marker of Allergic Inflammation
© Copyright: Yonsei University College of Medicine 2017.
PURPOSE: CD93 is receiving renewed attention as a biomarker of inflammation. We aimed to evaluate the potential for serum sCD93 to serve as a novel biomarker for allergic inflammation.
MATERIALS AND METHODS: We enrolled 348 subjects with an allergic disease [allergic rhinitis (AR), chronic spontaneous urticaria (CSU), or bronchial asthma (BA)], including 14 steroid-naïve BA patients who were serially followed-up.
RESULTS: The serum sCD93 levels (ng/mL) in patients with exacerbated AR (mean±standard deviation, 153.1±58.4) were significantly higher than in patients without AR (132.2±49.0) or with stable AR (122.3±42.1). Serum sCD93 levels in exacerbated CSU (169.5±42.8) were also significantly higher than those in non-CSU (132.4±51.6) and stable CSU (122.8±36.2). This trend was also seen in BA. Serum levels in patients with ICS-naïve BA (161.4±53.1) were significantly higher than those in healthy controls without BA (112.2±30.8), low- and medium-dose ICS users. Serum sCD93 levels in high-dose ICS users (72.2±20.6) were significantly lower than those in low- and medium-dose users. The serum sCD93 levels in steroid-naïve patients with BA (195.1±72.7) decreased after ICS use for 4 weeks (134.4±42.8) and 8 weeks (100.7±13.4), serially.
CONCLUSION: Elevated serum sCD93 levels reflected exacerbated status of allergic diseases, including CSU, AR, and asthma. ICS use significantly diminished serum sCD93 levels in steroid-naïve patients with BA. This result may suggest sCD93 in serum as a therapeutic marker for allergic inflammation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:58 |
|---|---|
| Enthalten in: |
Yonsei medical journal - 58(2017), 3 vom: 19. Mai, Seite 598-603 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Park, Hye Jung [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Allergy |
|---|
| Anmerkungen: |
Date Completed 10.05.2017 Date Revised 02.12.2018 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3349/ymj.2017.58.3.598 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM270214739 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM270214739 | ||
| 003 | DE-627 | ||
| 005 | 20231224230056.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3349/ymj.2017.58.3.598 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0900.xml |
| 035 | |a (DE-627)NLM270214739 | ||
| 035 | |a (NLM)28332366 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Park, Hye Jung |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Soluble CD93 in Serum as a Marker of Allergic Inflammation |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.05.2017 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Copyright: Yonsei University College of Medicine 2017 | ||
| 520 | |a PURPOSE: CD93 is receiving renewed attention as a biomarker of inflammation. We aimed to evaluate the potential for serum sCD93 to serve as a novel biomarker for allergic inflammation | ||
| 520 | |a MATERIALS AND METHODS: We enrolled 348 subjects with an allergic disease [allergic rhinitis (AR), chronic spontaneous urticaria (CSU), or bronchial asthma (BA)], including 14 steroid-naïve BA patients who were serially followed-up | ||
| 520 | |a RESULTS: The serum sCD93 levels (ng/mL) in patients with exacerbated AR (mean±standard deviation, 153.1±58.4) were significantly higher than in patients without AR (132.2±49.0) or with stable AR (122.3±42.1). Serum sCD93 levels in exacerbated CSU (169.5±42.8) were also significantly higher than those in non-CSU (132.4±51.6) and stable CSU (122.8±36.2). This trend was also seen in BA. Serum levels in patients with ICS-naïve BA (161.4±53.1) were significantly higher than those in healthy controls without BA (112.2±30.8), low- and medium-dose ICS users. Serum sCD93 levels in high-dose ICS users (72.2±20.6) were significantly lower than those in low- and medium-dose users. The serum sCD93 levels in steroid-naïve patients with BA (195.1±72.7) decreased after ICS use for 4 weeks (134.4±42.8) and 8 weeks (100.7±13.4), serially | ||
| 520 | |a CONCLUSION: Elevated serum sCD93 levels reflected exacerbated status of allergic diseases, including CSU, AR, and asthma. ICS use significantly diminished serum sCD93 levels in steroid-naïve patients with BA. This result may suggest sCD93 in serum as a therapeutic marker for allergic inflammation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Allergy | |
| 650 | 4 | |a asthma | |
| 650 | 4 | |a biomarker | |
| 650 | 4 | |a inhaled corticosteroid | |
| 650 | 4 | |a soluble CD93 | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Membrane Glycoproteins |2 NLM | |
| 650 | 7 | |a Receptors, Complement |2 NLM | |
| 650 | 7 | |a complement 1q receptor |2 NLM | |
| 700 | 1 | |a Han, Heejae |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Sang Chul |e verfasserin |4 aut | |
| 700 | 1 | |a Son, Young Woong |e verfasserin |4 aut | |
| 700 | 1 | |a Sim, Da Woon |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Kyung Hee |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Yoon Hee |e verfasserin |4 aut | |
| 700 | 1 | |a Jeong, Kyoung Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Jung Won |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jae Hyun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Yonsei medical journal |d 1963 |g 58(2017), 3 vom: 19. Mai, Seite 598-603 |w (DE-627)NLM00031269X |x 1976-2437 |7 nnns |
| 773 | 1 | 8 | |g volume:58 |g year:2017 |g number:3 |g day:19 |g month:05 |g pages:598-603 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3349/ymj.2017.58.3.598 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 58 |j 2017 |e 3 |b 19 |c 05 |h 598-603 | ||